Explore

Trendline Trendline
Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech

Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech

Jasper Therapeutics and Kira Pharma Merge to Form Immunology-Focused Biotech
Trendline Trendline
Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Cancer Treatment Pipeline with New CLDN6 Binder
Rapid Read Rapid Read
Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Umeå University Develops Antibody Drug to Halt Aggressive Prostate Cancer Spread

Researchers at Umeå University, in collaboration with other institutions, have developed an experimental antibody drug aimed at slowing tumor growth and preventing the spread of aggressive prostate cancer. The study, published in Signal Transduction and Targeted Therapy, highlights the creation of a fully human antibody designed to prevent metastasis. This antibody, made entirely from human proteins, has shown promise in preclinical studies by stopping tumor growth and metastatic spread in aggressive prostate cancer. The research, led by Professor Maréne Landström, identifies a new mechanism that could potentially lower the risk of side effects. The development of this drug is a significant step towards creating a treatment that could improve survival rates and quality of life for men with advanced prostate cancer.
Trendline Trendline
Biotech Sector Eyes Mental Health Crisis as Next Major Investment Opportunity

Biotech Sector Eyes Mental Health Crisis as Next Major Investment Opportunity

Biotech Sector Eyes Mental Health Crisis as Next Major Investment Opportunity
Trendline Trendline
Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models
Rapid Read Rapid Read
Type 1 Diabetes Research Advances Toward Insulin Independence

Type 1 Diabetes Research Advances Toward Insulin Independence

Significant progress is being made in the treatment of type 1 diabetes (T1D), with new therapies aiming to achieve insulin independence for patients. Innovations include Sanofi's Tzield, the first disease-modifying therapy for pediatric patients with stage 3 T1D, and SAB Biotherapeutics' SAB-142, which combines human and animal-derived antibodies to improve glycemic control. Eledon Pharmaceuticals is developing tegoprubart, which has shown promise in achieving insulin independence in patients post-cellular transplant surgery. These developments are part of a broader effort to move beyond traditional insulin-based treatments, offering new hope for patients with T1D.
Vox Vox
An HIV vaccine is within reach

An HIV vaccine is within reach

But politics could derail the one thing to unlock it.
Trendline Trendline
Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder

Verismo Therapeutics Expands Solid Tumor Treatment Pipeline with New CLDN6 Binder
Rapid Read Rapid Read
Jeremy Clarkson's Prostate Cancer Treatment Highlights Potential of Focal Therapy

Jeremy Clarkson's Prostate Cancer Treatment Highlights Potential of Focal Therapy

A 10-year study led by Imperial College London has found that focal therapy, a targeted treatment for prostate cancer, may be as effective as traditional methods like surgery or radiotherapy, with fewer side effects. Jeremy Clarkson, who underwent this treatment, has brought attention to its benefits. The study followed nearly 3,500 men and found that focal therapy significantly reduces the risk of complications such as urinary incontinence and erectile dysfunction, while maintaining effective cancer control.
Rapid Read Rapid Read
Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics Announces Promising Phase 2 Results for K8 in Geographic Atrophy

Inflammasome Therapeutics has reported positive results from a Phase 2 clinical trial of its investigational drug K8 for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration. The trial demonstrated that K8 significantly slowed the progression of GA and improved visual acuity over a six-month period. The study involved 30 participants with bilateral GA, and the drug was administered as a bioerodible sustained-release intravitreal implant. The 0.7 mg dose cohort showed a 54% reduction in the mean rate of GA growth compared to the control group, and a 4.0-letter mean advantage in best-corrected visual acuity was observed. These results were presented at the American Society of Retina Specialists Annual Meeting in Montreal.
Trendline Trendline
CRISPR Technology Advances with Epigenetic Editing in Clinical Trials

CRISPR Technology Advances with Epigenetic Editing in Clinical Trials

CRISPR Technology Advances with Epigenetic Editing in Clinical Trials
Trendline Trendline
Gene Therapy Shows Promise in Reversing Fragile X Syndrome Traits

Gene Therapy Shows Promise in Reversing Fragile X Syndrome Traits

Gene Therapy Shows Promise in Reversing Fragile X Syndrome Traits